Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antipsychotic
Biotech
Karuna's journey from 'serendipitous clinical finding' to FDA
Karuna's Andrew Miller details the long journey to get KarXT from Eli Lilly’s storeroom all the way to the FDA for schizophrenia.
Annalee Armstrong
Oct 4, 2023 6:00am
Cerevel stock doubles on success of phase 1b schizophrenia trial
Jun 30, 2021 7:15am
Acadia adds pain meds to the pipeline with $52.5M CerSci buyout
Aug 25, 2020 3:57pm
Could I-O drugs get a boost from an existing antipsychotic drug?
Mar 6, 2020 9:30am
Intra-Cellular raises $150M as it preps schizophrenia drug filing
Oct 3, 2017 7:35am
Biotech IPOs; CHMP knockbacks—News of Note
Jul 21, 2017 8:25am